China Pharmaceutical Industry Research and Development Association

Name

China Pharmaceutical Industry Research and Development Association

Legal name

中国化学制药工业协会

Website

https://cpia.org.cn

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association Services

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industries

International Standards Development & Standardization Bodies (BPADANAA), Technical Committees, Working Groups & Expert Panels (BPADANAB), Environmental, Climate & Sustainability Standards & Reporting Cooperation (BPADANAI)

Keywords

• Pharmaceutical industry association
• Policy advocacy services
• Pharmaceutical market research
• Industry standards development
• Professional training services

Headquarters

HQ city

Changyang

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Core offering

The association provides organization-level policy advocacy and interpretation, industry research, coordination, self-regulation and standardization support, and member communications for China's chemical pharmaceutical sector. Its portfolio also includes conferences, training, industry publications, and digital systems for brand applications, statistical reporting, and credit information.

Product overview

China Pharmaceutical Industry Research and Development Association (CPIA) offers a portfolio of industry information services, publications, and digital platforms. The core offerings include the annual China Pharmaceutical Industry Development Report (Blue Book of Pharmaceutical Industry) and the periodic China Pharmaceutical Information publication containing market reports and import/export analysis. The association operates multiple digital service platforms including the Brand Application System for company registrations, the Statistical Direct Reporting System for industry data collection, the Integrity Medical Healthcare Network for credit information, and an internal email system for member communications. These products and services collectively serve the chemical pharmaceutical industry's information needs, policy coordination, and regulatory compliance requirements.

Differentiator

Problem solved

Functional benefit

Products and services

• China Pharmaceutical Industry Development Report (2025) (《中国制药工业发展报告（2025）》) Annual report covering China's pharmaceutical manufacturing industry with comprehensive industry analysis and statistics.
• China Pharmaceutical Information (《中国制药信息》) Periodic industry information publication providing market reports, import/export analysis, and production statistics for chemical pharmaceuticals.
• Brand Application System (品牌申报系统) Online system for pharmaceutical companies to submit brand-related applications and declarations to the association.
• Statistical Direct Reporting System (统计直报系统) Online system for collecting pharmaceutical-industry data directly from member companies.
• Integrity Medical Healthcare Network (诚信医药卫生网) Platform providing credit information and ratings for pharmaceutical companies and medical and healthcare organizations.

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• 生态环境部抗生素菌渣无害化处理与资源化利用工程技术中心 (Engineering Center for Antibiotic Residue Harmless Treatment and Resource Utilization, Ministry of Ecology and Environment)coreStrategic or Co-development PartnerThe association collaborated with this engineering center on research regarding antibiotic residue treatment and new pollutant control. This partnership focuses on environmental protection technologies and standard formulation for the pharmaceutical industry.
• 中国环境科学研究院 (Chinese Research Academy of Environmental Sciences)coreStrategic or Co-development PartnerPartnered with CPIA on pharmaceutical industry pollution control and environmental standards research. The academy provides technical expertise for wastewater treatment standards and regulatory policy development.
• 哈尔滨工业大学(深圳) (Harbin Institute of Technology, Shenzhen)coreStrategic or Co-development PartnerAcademic partnership for environmental technology research in the pharmaceutical sector, particularly regarding waste treatment and resource efficiency technologies.
• 石家庄四药集团河北广祥制药有限公司 (Shijiazhuang No.4 Pharmaceutical Group Hebei Guangxiang Pharmaceutical Co., Ltd.)minorStrategic or Co-development PartnerCPIA led an expert research team to visit this pharmaceutical manufacturer to investigate antibiotic residue treatment and new pollutant prevention, demonstrating industry-research collaboration.
• 中国科学院生态环境研究中心 (Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences)coreStrategic or Co-development PartnerCollaboration on antibiotic resistance research and pollution emission management policies, addressing global public health threats from antibiotic pollution.
• 中国科学院理化技术研究所 (Institute of Chemistry, Chinese Academy of Sciences)coreStrategic or Co-development PartnerPartnership on zero-carbon factory construction technologies and thermal energy solutions for pharmaceutical manufacturing.

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Global pharma industry association headquartered in Geneva. Comparable as a peer-level industry association performing policy advocacy and member services, though at international rather than national scale, making it useful as a structural/template benchmark.
• China Association of Pharmaceutical Commerce: National pharmaceutical commerce/distribution association. Comparable as a parallel member-association in the pharma value chain with similar government supervision and dues model, but focused on distribution rather than manufacturing.
• China Chamber of Commerce for Import and Export of Medicines and Health Products: A national chamber of commerce covering import/export of medicines and health products. Comparable as a membership-based organization with government ties that serves the pharmaceutical trade ecosystem, though its mandate is trade-flow oriented rather than manufacturing-industry focused.

Emerging players

• China Pharmaceutical Packaging Association: Industry association covering pharmaceutical packaging. Comparable as a sibling national industry association in the pharma supply chain with similar dues-funded operating model, competing for ancillary members but on a narrower sub-vertical.
• China Nonprescription Medicines Association: National association representing OTC/nonprescription medicines. Comparable as a focused industry association serving a sub-segment of the Chinese pharmaceutical market, with similar member-service and policy advocacy functions, competing for OTC-oriented member companies.

Direct peers

• Chinese Pharmaceutical Association (CPA): The leading scientific/academic pharmaceutical association in China, registered with the Ministry of Civil Affairs and affiliated with the Chinese Medical Association. Directly comparable as a national pharma member-association serving overlapping industry stakeholders, with a science-and-research rather than industrial-policy emphasis.
• China Pharmaceutical Industry Association (CPIA — the broader medical industry association): The umbrella 'China Pharmaceutical Industry Association' (中国医药行业协会) covers a wider remit across the entire pharma value chain versus CPIA's chemical-pharma specialization. It is the most direct comparator given the similar name, government-supervised status, and shared member base in China's pharmaceutical industry.
• R&D-based Pharmaceutical Association Committee (RDPAC): RDPAC represents multinational R&D-based pharmaceutical companies in China and operates as an industry association under a similar government-engagement model. Directly comparable as a pharma industry association that performs policy advocacy, member services, and standards coordination for pharmaceutical companies operating in China.
• China Pharmaceutical Innovation Association (CPIA / PhIRDA): Industry association promoting pharmaceutical innovation and R&D in China. Comparable as a national pharma industry association with strong government ties that competes for the same member companies and overlapping policy advocacy mandate, but with an innovation/R&D emphasis versus CPIA's manufacturing/chemical orientation.
• China Biochemical Pharmaceutical Industry Association: National-level industry association focused on the biochemical pharmaceutical sub-sector. Comparable as a sibling industrial-pharma association with similar structure (member dues, committees, policy advocacy), competing for the same chemical-pharma member enterprises on a sub-vertical basis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/china-pharmaceutical-industry-association

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about China Pharmaceutical Industry Research and Development Association